# Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients

> **NCT04747275** · PHASE4 · TERMINATED · sponsor: **Children's Mercy Hospital Kansas City** · enrollment: 6 (actual)

## Conditions studied

- Hypothyroidism
- Trisomy 21

## Interventions

- **DRUG:** Liquid stable levothyroxine (L-T4) Tirosint-SOL
- **DRUG:** Oral tablet levothyroxine (L-T4)

## Key facts

- **NCT ID:** NCT04747275
- **Lead sponsor:** Children's Mercy Hospital Kansas City
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-18
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-11-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Transitioned to multi site study with sponsor
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04747275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04747275, "Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04747275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*